About the Prognosis Of Lung Cancer Session
Lung cancer prognosis hinges on various factors like cancer stage, type, and patient health. Early detection significantly improves outcomes. For non-small cell lung cancer (NSCLC), the most common type, the five-year survival rate varies from around 25% for stage 3 to 65% for stage 1A. Small cell lung cancer (SCLC) generally has a poorer prognosis, with a five-year survival rate of around 6%. Advanced treatments, including targeted therapies and immunotherapy, have shown promise in extending survival and improving quality of life. Additionally, advancements in precision medicine, utilizing genetic testing to tailor treatments, offer hope for better outcomes. However, challenges like drug resistance persist, necessitating ongoing research into innovative therapies to enhance lung cancer prognosis.
Topics Covered in Prognosis Of Lung Cancer
TNM Staging
Histologic Subtype
Performance Status
Driver Mutations
Circulating Tumor DNA
Survival Prediction
Related Scientific Sessions at CIOC 2027
Why Attend the Prognosis Of Lung Cancer Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Prognosis Of Lung Cancer work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Prognosis Of Lung Cancer research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Prognosis Of Lung Cancer track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Prognosis Of Lung Cancer Conference 2027 — FAQs
What is the Prognosis Of Lung Cancer track at CIOC 2027?
The Prognosis Of Lung Cancer track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Prognosis Of Lung Cancer. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Prognosis Of Lung Cancer sessions?
Cancer researchers and clinicians, educators and students with an interest in Prognosis Of Lung Cancer are all welcome — whether presenting or attending.
Can I present my research in the Prognosis Of Lung Cancer track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Prognosis Of Lung Cancer sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Prognosis Of Lung Cancer track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.